UNSPSC 51172308: Methylene blue or methylthioninium chloride

This classification denotes a dye with the molecular formula C16H18N3S.Cl.3H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier T42P99266K, chemically known as 3,7-bis(dimethylamino)phenothiazin-5-ium chloride but more generally known as basic blue 9, which bears US NIH Compound Identifier 6099. European Medicines Agency schedules Methylene blue in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21957. Methylene blue bears US NLM identifiers UMLS ID C0025746 and NCI Concept Code C644.

SMILES: S1C2C(NC3C1CC(N(C)C)CC3)CCC(=[N](\C)C)/C2.

UNSPSC 51172308 Methylene blue or methylthioninium chloride, a Commodity code, covers pharmaceutical chemical compounds and active pharmaceutical ingredients sourced by state and local health and human services agencies for clinical laboratory testing, correctional health services, and pharmacy benefit programs. State and local governments purchase this substance primarily as a reagent or active pharmaceutical ingredient for drug screening applications, particularly in correctional and community supervision settings where immunoassay and confirmatory testing protocols require it. Issuing bodies include county community supervision and corrections departments, state health and human services commissions, and cooperative purchasing alliances spanning multiple states and local jurisdictions. The scope of work encompasses supply of the chemical compound to support specimen collection and drug testing operations, laboratory certification and compliance with SAMHSA, state pharmacy boards, and FDA manufacturing requirements, and integration into multi-source pharmaceutical procurement frameworks serving state agencies and participating municipalities.

The code shows recent activity in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with a response deadline of July 23, 2026; the estimated contract value is $600,000 over two years with three optional one-year renewals, and the scope encompasses immunoassay screening with confirmatory testing at two sites in Plano and McKinney, with approximately 25,031 tests annually across five- and six-panel drug screens. The Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to supply products through three authorized wholesalers and maintain cGMP and Drug Supply Chain Security Act compliance; awarded vendors will be effective July 1, 2026, under a two-year contract with optional extensions. The Texas Health and Human Services Commission also issued RFI HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs, signaling future procurement activity in pharmaceutical supply arrangements outside traditional pharmacy benefit manager channels.